Dr. Lal Path Labs Ltd.
5,069words
3turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs
40
10.5%
48%
240%
Rs. 731 crore
Rs. 660 crore
10.7%
Rs. 224 crore
Rs. 202 crore
10.8%
Rs. 152 crore
Rs. 131 crore
Guidance — 4 items
Chief Executive Officer said
opening
“Ved Prakash Goel, Group CFO & CEO – International Business said: “Q2 FY26 marked a healthy revenue growth trajectory on the back of a robust sample volume growth.”
Chief Executive Officer said
opening
“Moving forward, growth will be underpinned by geographic expansion, portfolio innovation and digital enablement.”
Chief Executive Officer said
opening
“Our operational priority remains to maximize network utilization and convert infrastructure into significant operating leverage, ensuring we deliver superior, sustainable, and profitable growth for our shareholders.” “Q2 FY26 demonstrated steady growth in volumes and favourable business mix, driving sustained financial performance.”
Chief Executive Officer said
opening
“In FY25 & FY24, DLPL collected and processed approximately 86 million samples and 78 million samples from 28.8 million and 27.6 million patients, respectively.”
Advertisement
Speaking time
1
1
1
Opening remarks
Executive Chairman said
“At Dr. Lal PathLabs, we see this decade as one for deep transformation. The burden of chronic and lifestyle-related diseases continues to rise, demanding greater focus on early detection and continuous monitoring. As new therapies for diabetes, hypertension and obesity become more widely available, the role of diagnostics will only intensify. Further, as policy initiatives like Ayushman Bharat expand access across Tier-2 and Tier-3 regions, diagnostics is emerging as the essential first step in care delivery. The growing awareness around preventive health, supported by rapid digital adoption, is helping millions of citizens engage with organized healthcare for the first time. This convergence of accessibility, affordability, and accountability marks a defining moment for the sector, and we are privileged to play a prime role in it. As the shift from unorganized to organized healthcare continues, we stand ready to lead the way responsibly and to contribute meaningfully to India’s ambit
Chief Executive Officer said
Commenting on the performance, Mr. Ved Prakash Goel, Group CFO & CEO – International Business said: “Q2 FY26 marked a healthy revenue growth trajectory on the back of a robust sample volume growth. As we continue to focus on improving patient service, enhancing medical expertise and network expansion, this momentum is expected to continue. We continue to broaden our high-complexity testing capabilities, including Genomics, Oncology, Autoimmunity and others. We are also increasing applications for AI in our operations, including in- house developed algorithms. Digital and automation initiatives remain central to improving operational efficiency, enhancing patient experience, and supporting scalable growth. Moving forward, growth will be underpinned by geographic expansion, portfolio innovation and digital enablement. Our pricing discipline continues to serve as a powerful lever, and is expected to support movement from unorganized to organized players. Our operational priority remains t
For further information please contact
Ved Prakash Goel Dr. Lal PathLabs Limited Tel: +91 124 301 6500 Fax: +91 124 423 4468 E-mail: ved.goel@lalpathlabs.com Siddharth Rangnekar / Nishid Solanki CDR India Tel: +91 22 66451209 / 1221 Fax: +91 22 66451213 Email: siddharth@cdr-india.com / nishid@cdr-india.com 39 Thank You 40
Advertisement